- Home
- ADSK vs REGN Comparison
ADSK vs REGN Comparison
Compare ADSK & REGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ADSK
- REGN
- Stock Information
- Founded
- ADSK 1982
- REGN 1988
- Country
- ADSK United States
- REGN United States
- Employees
- ADSK N/A
- REGN N/A
- Industry
- ADSK Computer Software: Prepackaged Software
- REGN Biotechnology: Pharmaceutical Preparations
- Sector
- ADSK Technology
- REGN Health Care
- Exchange
- ADSK Nasdaq
- REGN Nasdaq
- Market Cap
- ADSK 63.8B
- REGN 63.4B
- IPO Year
- ADSK N/A
- REGN 1991
- Fundamental
- Price
- ADSK $295.66
- REGN $508.90
- Analyst Decision
- ADSK Buy
- REGN Buy
- Analyst Count
- ADSK 23
- REGN 23
- Target Price
- ADSK $335.17
- REGN $854.26
- AVG Volume (30 Days)
- ADSK 1.5M
- REGN 1.5M
- Earning Date
- ADSK 05-22-2025
- REGN 07-31-2025
- Dividend Yield
- ADSK N/A
- REGN 0.35%
- EPS Growth
- ADSK 1.35
- REGN 16.49
- EPS
- ADSK 4.66
- REGN 39.43
- Revenue
- ADSK $6,347,000,000.00
- REGN $14,085,700,000.00
- Revenue This Year
- ADSK $15.89
- REGN N/A
- Revenue Next Year
- ADSK $11.10
- REGN $6.83
- P/E Ratio
- ADSK $63.48
- REGN $12.92
- Revenue Growth
- ADSK 12.44
- REGN 7.52
- 52 Week Low
- ADSK $223.03
- REGN $476.49
- 52 Week High
- ADSK $326.62
- REGN $1,211.20
- Technical
- Relative Strength Index (RSI)
- ADSK 57.11
- REGN 41.90
- Support Level
- ADSK $293.76
- REGN $503.25
- Resistance Level
- ADSK $300.52
- REGN $538.20
- Average True Range (ATR)
- ADSK 4.36
- REGN 15.52
- MACD
- ADSK -0.97
- REGN 1.72
- Stochastic Oscillator
- ADSK 73.70
- REGN 58.56
About ADSK Autodesk Inc.
Founded in 1982, Autodesk is an application software company that serves industries in architecture, engineering, and construction; product design and manufacturing; and media and entertainment. Autodesk software enables design, modeling, and rendering needs of these industries. The company has over 4 million paid subscribers across 180 countries.
About REGN Regeneron Pharmaceuticals Inc.
Regeneron Pharmaceuticals Inc discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and Crispr-based gene editing (Intellia).